The following trials provide information to treat various types of cancer and infectious disease, both for ongoing and completed clinical trials. For more information on our oncology therapy area please click here or for our infection therapy area please click here.
- collapse A survey conducted to evaluate and assess the factors influencing therapeutic adherence among early breast cancer patients treated with the aromatase inhibitor ARIMIDEX
- collapse A Phase I, open label, single-centre study to assess the safety and tolerability of the Tor Kinase Inhibitor AZD8055 administered orally to Japanese patients with advanced solid tumours
- collapse A Phase I/II, Open-Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients With Advanced Solid Tumours, Lymphomas and Endometrial Carcinoma.
- collapse A Phase-1, Single Center, Double Blind, Randomized, Placebo-controlled, Parallel-group Study to assess the Safety, Tolerability and Pharmacokinetics of Intravenous AZD9742 after Single Ascending Doses in Healthy Male and Female Subjects
- collapse A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days
- collapse Reasons for Changing HOrmonal Therapy of Advanced Breast Cancer (HOT ABC)
- collapse A Phase I, Double-blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability, and Pharmacokinetics of a Single Dose of AZD9742 in Healthy Elderly Male and Female Volunteers
- collapse A Phase 1, Open-Label, Non-randomized, Single-Center Study to Assess Distribution, Metabolism and Excretion After [14C]-Labelled Intravenous Administration of AZD9742 as a 2-hour Infusion to Healthy Male Volunteers
- collapse Observational Study to Assess Clinical Management Patterns in Patients With Hospitalised Community-Acquired Pneumonia (CAP) or Complicated Skin and Skin Structure Infections (cSSSI)
- collapse A Phase II Randomised Factorial Double-blind Study to Investigate the Management of AZD2171-induced Hypertension and Efficacy of AZD2171 at Doses of 30 mg and 45 mg in Patients with Advanced Solid Tumours
